- Home
- SOL vs QNCX Comparison
SOL vs QNCX Comparison
Compare SOL & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOL
- QNCX
- Stock Information
- Founded
- SOL 2005
- QNCX 2012
- Country
- SOL United States
- QNCX United States
- Employees
- SOL N/A
- QNCX N/A
- Industry
- SOL Semiconductors
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SOL Technology
- QNCX Health Care
- Exchange
- SOL Nasdaq
- QNCX Nasdaq
- Market Cap
- SOL 98.5M
- QNCX 88.6M
- IPO Year
- SOL 2008
- QNCX 2019
- Fundamental
- Price
- SOL $1.79
- QNCX $2.53
- Analyst Decision
- SOL Strong Buy
- QNCX Strong Buy
- Analyst Count
- SOL 2
- QNCX 4
- Target Price
- SOL $4.50
- QNCX $7.75
- AVG Volume (30 Days)
- SOL 154.1K
- QNCX 493.7K
- Earning Date
- SOL 11-14-2025
- QNCX 11-12-2025
- Dividend Yield
- SOL N/A
- QNCX N/A
- EPS Growth
- SOL N/A
- QNCX N/A
- EPS
- SOL N/A
- QNCX N/A
- Revenue
- SOL $71,226,000.00
- QNCX N/A
- Revenue This Year
- SOL N/A
- QNCX N/A
- Revenue Next Year
- SOL $45.37
- QNCX N/A
- P/E Ratio
- SOL N/A
- QNCX N/A
- Revenue Growth
- SOL N/A
- QNCX N/A
- 52 Week Low
- SOL $1.04
- QNCX $0.72
- 52 Week High
- SOL $2.30
- QNCX $2.70
- Technical
- Relative Strength Index (RSI)
- SOL 38.62
- QNCX 81.77
- Support Level
- SOL $1.76
- QNCX $1.61
- Resistance Level
- SOL $1.85
- QNCX $1.84
- Average True Range (ATR)
- SOL 0.04
- QNCX 0.19
- MACD
- SOL -0.01
- QNCX 0.08
- Stochastic Oscillator
- SOL 22.14
- QNCX 88.10
About SOL Emeren Group Ltd each representing 10 shares
Emeren Group Ltd is a renewable energy producer. Its portfolio consists of solar projects and Independent Power Producer (IPP) assets, and it also has globalised Battery Energy Storage System (BESS) capacity. The group specializes in the solar project lifecycle, development, and from construction to financing. It has three reportable segments; Solar power project development, EPC services, and Electricity generation. Majority of revenue is From Electricity Generation. The company operates in China, USA, Germany, UK, Spain, France, Poland, Italy, Hungary, Luxembourg. Majority of revenue is from Italy.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.